Search Tag: atrial fibrillation
2025 01 Sep
Pulsed field ablation (PFA) was not superior to radiofrequency ablation (RFA) in patients with drug-resistant paroxysmal atrial fibrillation (AF), according to results from the late-breaking BEAT-PAROX-AF trial presented in a Hot Line session at ESC Congress 2025. AF is the most common sustained cardiac arrhythmia. When antiarrhythmic drug1Read more
2025 01 Sep
Discontinuing oral anticoagulation (OAC) therapy lowered the risk of a composite endpoint of stroke, systemic embolism, or major bleeding compared with continuing OAC in patients who had undergone successful atrial fibrillation (AF) ablation at least 12 months earlier, according to results from the late-breaking ALONE-AF (Anticoagulation One year 1Read more
2025 07 Jul
Stroke remains a major global cause of mortality, with ischaemic stroke accounting for the majority of cases. Atrial fibrillation (AF), the most common cardiac arrhythmia, significantly contributes to this risk by promoting thrombus formation, particularly within the left atrial appendage (LAA). The CHA₂DS₂-VASc score, a widely used clinical 1Read more
2025 25 Jun
Atrial fibrillation (AF) accounts for about 20–30% of ischaemic strokes. Direct oral anticoagulants (DOACs) are very effective for long-term secondary prevention of ischaemic stroke in AF patients, reducing the risk of intracranial haemorrhage by about half compared to vitamin K antagonists. However, the best timing to start anticoagulation after 1Read more
2025 25 Jun
Atrial fibrillation (AF) accounts for about 20–30% of ischaemic strokes. Direct oral anticoagulants (DOACs) are very effective for long-term secondary prevention of ischaemic stroke in AF patients, reducing the risk of intracranial haemorrhage by about half compared to vitamin K antagonists. However, the best timing to start anticoagulation after 1Read more
2025 11 Jun
Atrial fibrillation (AF) presents significant management challenges in the ICU. Pre-existing AF affects 10–20% of ICU patients, while new-onset AF (NOAF) occurs in 5–15% of critically ill individuals and up to 46% in those with septic shock. NOAF may be transient or indicate an underlying predisposition, complicating treatment decisions. 1Read more
2025 20 May
Clinical insights on the use of beta-blockers and vasopressors in the ICU, focusing on landiolol and vasopressin. When managing cardiovascular instability in critically ill patients, intensivists often face a delicate balancing act: controlling heart rate without compromising haemodynamics and maintaining perfusion without excessive va1Read more
2025 08 Jan
Drinking multiple cups of coffee daily may help protect against cognitive decline in individuals with atrial fibrillation (AFib), according to research published in the Journal of the American Heart Association . This recent study found no reason to discourage patients with AFib from enjoying coffee. It might even be beneficial, as highli1Read more
2024 27 Nov
U.S. FDA approves AOP Health’s Rapiblyk™ (landiolol) for Atrial Fibrillation and Atrial Flutter in the critical care setting. AOP Orphan Pharmaceuticals GmbH (AOP Health) , based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for Rapiblyk TM (landiolol) in the hospital cr1Read more
2024 14 Oct
According to a new scientific statement from the American Heart Association, three common cardiovascular diseases in adults—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and an increased risk of dementia. The statement reviews current research on the relationship between cardiovascular and b1Read more
2024 02 Sep
According to research presented at the ESC Congress 2024 in London, screening for atrial fibrillation (AF) with a wearable heart monitor over a two-week period can identify older adults with this potentially dangerous heart rhythm disorder but does not reduce the risk of subsequent strokes. However, the trial was cut short due to the COVID-191Read more
2024 01 Sep
Adherence to atrial fibrillation (AF) guideline recommendations in clinical practice across Europe was found to be poor, but a structured educational programme for healthcare professionals significantly improved the implementation of heart rhythm control recommendations, according to research presented in a Hot Line session at the ESC Congres1Read more
2024 26 Aug
Researchers at Mass General Brigham found that women have a lower risk of developing postoperative atrial fibrillation (poAF) after surgery compared to men but face a higher risk of long-term mortality once poAF occurs. The study is published in JAMA. The objective of the research was to identify the protective factors that reduce the incid1Read more
2024 16 Jul
A study published in Nature Medicine has demonstrated the clinical value of monitoring heart rate and physical activity using consumer wearable devices by comparing the response to two treatments for atrial fibrillation and heart failure. The study investigated whether commercially available fitness trackers and smartphones could continu1Read more
2024 09 May
Over the past decade, late gadolinium-enhanced (LGE) cardiac MRI has been crucial in assessing left atrial (LA) fibrosis in atrial fibrillation (AF) patients, aiding in predicting AF recurrence post-ablation. This fibrotic burden can guide treatment decisions. Typically, imaging protocols involve a time-consuming diaphragm-navigated (dNAV) se1Read more
2024 09 May
Over the past decade, late gadolinium-enhanced (LGE) cardiac MRI has been crucial in assessing left atrial (LA) fibrosis in atrial fibrillation (AF) patients, aiding in predicting AF recurrence post-ablation. This fibrotic burden can guide treatment decisions. Typically, imaging protocols involve a time-consuming diaphragm-navigated (dNAV) se1Read more
2024 08 May
The Food and Drug Administration (FDA) has made history by granting the Apple Watch approval as a digital health technology device. Specifically, the FDA has endorsed its atrial fibrillation (AFib) feature as a qualified tool in the Medical Device Development Tools (MDDT) programme. This feature aids in detecting irregular heart patterns and h1Read more
2024 24 Apr
Atrial fibrillation (AFib) is the most prevalent form of irregular heartbeat. It is projected to impact approximately 12.1 million adults in the United States by 2030. AFib results from abnormal electrical impulses causing a portion of the heart to quiver or fibrillate, often leading to complications and up to a fivefold increased risk of stroke. 1Read more
2023 25 Oct
Researchers at the Smidt Heart Institute at Cedars-Sinai have uncovered the potential of an artificial intelligence (AI) algorithm to detect abnormal heart rhythms in individuals who are not yet displaying symptoms. This innovative algorithm, capable of identifying concealed signals within common medical diagnostic tests, holds promise for aiding 1Read more
2023 06 Sep
Atrial fibrillation (AF) is a common cardiac arrhythmia. Research has consistently shown that AF heightens the risk of adverse outcomes in hospitalised and outpatient populations. Data suggests that newly developed AF (NAF) is common among critically ill patients, negatively impacting both short- and long-term outcomes, including prolonged hospita1Read more
2023 24 Aug
Integrating and analyzing data over time and across various data sources, CardioVisio for Atrial Fibrillation helps visualize the history of the patient’s heart and provides guideline-directed insights to healthcare providers. GE HealthCare announces the launch of CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to 1Read more
2022 09 Nov
The University of Cincinnati is part of a multimillion-dollar grant from the National Heart, Lung, and Blood Institute to study a strategy to prevent stroke in patients with atrial fibrillation. The trial will use an app on Apple Watch to monitor irregular heartbeat to reduce patients’ reliance on blood-thinning medication. “The individualised1Read more
2022 14 Oct
An overview of the clinical evidence demonstrating the effectiveness of landiolol for the treatment of atrial fibrillation or atrial flutter with heart failure and effective heart rate control during arrhythmias. Supraventricular arrhythmias (SVTs) are common in post-operative and cardiac ICUs. SVTs increase the risk of deat1Read more
2022 14 Oct
An overview of the clinical evidence demonstrating the effectiveness of landiolol for the treatment of atrial fibrillation or atrial flutter with heart failure and effective heart rate control during arrhythmias. Supraventricular arrhythmias (SVTs) are common in post-operative and cardiac ICUs. SVTs increase the risk of deat1Read more
2022 29 Aug
The latest research presented at the ESC Congress in Barcelona shows that conventional smartphone-assisted atrial fibrillation (AF) screening more than doubles the detection and treatment rate in older people compared to routine screening. AF is the most common heart rhythm disorder and affects over 40 million people worldwide. People with th1Read more
2022 09 Mar
As an initial remote monitoring diagnostic approach, Philips BioTel Heart MCOT detected 4.6 times more patients with atrial fibrillation compared to implantable loop recorder alone Almost eight times lower costs were achieved with improved detection rates and reduction of secondary stroke risk Remote cardiac monitoring via the1Read more
2021 28 Aug
In another Hot Line session at the ESC Congress 2021, findings from the ENVISAGE-TAVI AF showed that edoxaban is non-inferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation. The prevalence of pre-existing or new-onset atrial fibrillation after TAVI r1Read more
2021 06 Jul
The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial is the first randomised clinical trial of digoxin vs beta-blockers in patients with atrial fibrillation and heart failure symptoms. It is a unique trial as it uses patient and public involvement (PPI) in trial design and management. In other words, the RATE-AF tri1Read more
2021 22 Jun
Consumption of alcohol is associated with an increased risk of incident atrial fibrillation. Even a low spectrum of alcohol consumption could be a risk factor for atrial fibrillation. Alcohol consumption has been shown to have a consistent linear dose-response relationship when it comes to risk of AF. In a recent study, alcohol abstinence re1Read more